{
  "url": "https://struct.news/briefs/arcutis-turned-zoryve-demand-into-profit-its-cash-pile-still-shrank",
  "title": "Arcutis turned ZORYVE demand into profit. Its cash pile still shrank",
  "summary": "Inventory rose 138.2% year over year as three-month revenue climbed 59.3%.",
  "published_at": "2026-08-05T20:29:26.977449+00:00",
  "publisher": "Struct",
  "usage": "Figures are as reported by the company. Quote with attribution to the source filing.",
  "company": {
    "name": "Arcutis Biotherapeutics, Inc.",
    "ticker": "ARQT",
    "cik": "1787306",
    "sector": "Healthcare",
    "industry": "Biotechnology"
  },
  "source_filing": {
    "form": "10-Q",
    "filed": "2026-08-05",
    "accession": "0001787306-26-000051",
    "url": "https://www.sec.gov/Archives/edgar/data/1787306/000178730626000051/arqt-20260630.htm"
  },
  "comparison_filing": {
    "form": "10-Q",
    "filed": "2025-08-06",
    "url": "https://www.sec.gov/Archives/edgar/data/1787306/000178730625000124/arqt-20250630.htm"
  },
  "reported_figures": [
    {
      "group": "The filing in three numbers",
      "label": "Revenue",
      "value": 376072000,
      "display": "$376.1M",
      "unit": "usd",
      "period": "2025-12-31",
      "detail": null,
      "source": {
        "kind": "sec_filing",
        "label": "Filed company results",
        "form": "10-Q",
        "accession": "0001787306-26-000051",
        "filing_date": "2026-08-05"
      }
    },
    {
      "group": "The filing in three numbers",
      "label": "Revenue YoY",
      "value": 91.34434370261827,
      "display": "+91.3%",
      "unit": "percent",
      "period": "2025-12-31",
      "detail": null,
      "source": {
        "kind": "jodie_calculation",
        "label": "Calculated from filed company results",
        "form": "10-Q",
        "accession": "0001787306-26-000051",
        "filing_date": "2026-08-05"
      }
    },
    {
      "group": "The filing in three numbers",
      "label": "Operating margin",
      "value": -3.2512391244229826,
      "display": "-3.3%",
      "unit": "percent",
      "period": "2025-12-31",
      "detail": null,
      "source": {
        "kind": "jodie_calculation",
        "label": "Calculated from filed company results",
        "form": "10-Q",
        "accession": "0001787306-26-000051",
        "filing_date": "2026-08-05"
      }
    }
  ],
  "watch_next": [
    {
      "type": "product_pipeline",
      "statement": "R&D spending increased with the ARQ-234 milestone and is expected to keep rising as clinical development and ZORYVE expansions continue.",
      "importance": "medium",
      "evidence": "We expect research and development expenses to continue to increase in future periods, primarily due to our clinical development program for ARQ-234, as well as the development costs associated with ZORYVE label expansions and lifecycle management efforts.",
      "source_date": "2026-08-05"
    }
  ],
  "related_tickers": [
    "ARQT"
  ],
  "disclaimer": "Descriptive reporting of filed results. Not investment advice, and contains no forecast or recommendation."
}